BioTelemetry (BEAT) Tops Q3 EPS by 2c

BioTelemetry (NASDAQ: BEAT) reported Q3 EPS of $0.13, $0.02 better than the analyst estimate of $0.11. Revenue for the quarter came in at $43.5 million versus the consensus estimate of $46.05 million.

For earnings history and earnings-related data on BioTelemetry (BEAT) click here.

You May Also Be Interested In

• Raymond James Downgrades Phreesia Inc. (PHR) to Market Perform
• Barclays Downgrades Ipsen SA (IPN:FP) (IPSEF) to Underweight
• TD Cowen Reiterates Buy Rating on Boston Scientific (BSX)